[go: up one dir, main page]

NO175531C - Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider - Google Patents

Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider

Info

Publication number
NO175531C
NO175531C NO904689A NO904689A NO175531C NO 175531 C NO175531 C NO 175531C NO 904689 A NO904689 A NO 904689A NO 904689 A NO904689 A NO 904689A NO 175531 C NO175531 C NO 175531C
Authority
NO
Norway
Prior art keywords
preparation
acid amides
therapeutically active
analogous process
active imidazo
Prior art date
Application number
NO904689A
Other languages
English (en)
Norwegian (no)
Other versions
NO904689L (no
NO175531B (no
NO904689D0 (no
Inventor
Nicholas Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO904689D0 publication Critical patent/NO904689D0/no
Publication of NO904689L publication Critical patent/NO904689L/no
Publication of NO175531B publication Critical patent/NO175531B/no
Publication of NO175531C publication Critical patent/NO175531C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO904689A 1989-11-01 1990-10-30 Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider NO175531C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/430,228 US4943573A (en) 1989-11-01 1989-11-01 Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Publications (4)

Publication Number Publication Date
NO904689D0 NO904689D0 (no) 1990-10-30
NO904689L NO904689L (no) 1991-05-02
NO175531B NO175531B (no) 1994-07-18
NO175531C true NO175531C (no) 1994-10-26

Family

ID=23706624

Family Applications (1)

Application Number Title Priority Date Filing Date
NO904689A NO175531C (no) 1989-11-01 1990-10-30 Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider

Country Status (20)

Country Link
US (1) US4943573A (fi)
EP (1) EP0426180A3 (fi)
JP (1) JPH03169880A (fi)
KR (1) KR910009705A (fi)
CN (1) CN1025999C (fi)
AU (1) AU639033B2 (fi)
CA (1) CA2027935A1 (fi)
EG (1) EG19372A (fi)
FI (1) FI92697C (fi)
HU (1) HU209305B (fi)
IE (1) IE61579B1 (fi)
IL (1) IL96167A (fi)
MY (1) MY105308A (fi)
NO (1) NO175531C (fi)
NZ (1) NZ235868A (fi)
OA (1) OA09323A (fi)
PT (1) PT95765A (fi)
RU (1) RU2041210C1 (fi)
YU (1) YU205590A (fi)
ZA (1) ZA908725B (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5149699A (en) * 1991-10-24 1992-09-22 American Home Products Corporation Substituted pyridopyrimidines useful as antgiotensin II antagonists
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
TW593317B (en) 1993-06-21 2004-06-21 Janssen Pharmaceutica Nv Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996005202A1 (en) * 1994-08-17 1996-02-22 Nippon Hypox Laboratories Inc. Imidazoquinoline derivative
US5798767A (en) * 1996-03-15 1998-08-25 Rendition, Inc. Method and apparatus for performing color space conversion using blend logic
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
HUE026571T2 (hu) * 2006-08-02 2016-06-28 Cytokinetics Inc Adott kémiai anyagok, készítmények és imidazopiridineket magukba foglaló eljárások
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008121333A1 (en) * 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
CN120265631A (zh) * 2023-01-13 2025-07-04 上海超阳药业有限公司 喹啉酮化合物和萘啶酮化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
ZA851131B (en) * 1984-02-15 1986-09-24 Syntex Inc (2-oxo-1,2,3,5-tetrahydroimidazo-(2,1-b)quinazolinyl)oxyalkylamides
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Also Published As

Publication number Publication date
RU2041210C1 (ru) 1995-08-09
US4943573A (en) 1990-07-24
NO904689L (no) 1991-05-02
CA2027935A1 (en) 1991-05-02
KR910009705A (ko) 1991-06-28
FI905326A0 (fi) 1990-10-29
NO175531B (no) 1994-07-18
OA09323A (en) 1992-09-15
IL96167A (en) 1994-11-11
HU906977D0 (en) 1991-05-28
AU6567990A (en) 1991-05-23
NZ235868A (en) 1993-12-23
HU209305B (en) 1994-04-28
IL96167A0 (en) 1991-07-18
EG19372A (en) 1994-12-30
FI92697B (fi) 1994-09-15
JPH03169880A (ja) 1991-07-23
IE903923A1 (en) 1991-05-08
FI92697C (fi) 1994-12-27
CN1025999C (zh) 1994-09-28
NO904689D0 (no) 1990-10-30
CN1051359A (zh) 1991-05-15
ZA908725B (en) 1991-07-31
IE61579B1 (en) 1994-11-16
EP0426180A3 (en) 1992-01-08
PT95765A (pt) 1991-09-13
AU639033B2 (en) 1993-07-15
HUT56102A (en) 1991-07-29
MY105308A (en) 1994-09-30
YU205590A (sh) 1992-09-07
EP0426180A2 (en) 1991-05-08

Similar Documents

Publication Publication Date Title
NO175531C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider
NO179584C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler
FI890508L (fi) Menetelmä farmaseuttisesti aktiivisten 3-indolipalorypälehappojohdannaisten valmistamiseksi
FI883739A7 (fi) Menetelmä terapeuttisesti aktiivisten fenoksi-indaanimetyyliamiinijohdannaisten valmistamiseksi
NO180586C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte imidazoler
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
FI104174B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, 1,4-dihydro-4-okso-3-kinoliinikarboksyylihapon 7-[S,S]-2,8-diatsabisyklo[4.3.0]nonaani-isomeeriven valmistamiseksi
NO175978C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive bis-aza-bicykliske forbindelser
NO175100C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive 4(3H)-pteridinoner
FI893883A7 (fi) Menetelmä terapeuttisesti aktiivisten 7-tetrahydronaftyridiini-6-fluori-1,4-dihydro-4-oksokinoliini-3-karboksyylihappojen valmistamiseksi
FI900084A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsol-2-yyli- ja imidatso/4,5-b/pyridin-2-yyli-amino- ja -metyyli-1-piperidinyylietyylijohdannaisten valmistamiseksi
NO176273C (no) Analogifremgangsmåte for fremstilling av aktive substituerte benzamider
FI871087A7 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
FI885518A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5-dihydro-4-okso-5-isopropyyli-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
FI892908L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
FI903077A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia R(-)-3-kinuklidinolijohdannaisia
FI892684L (fi) Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
NO174203C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive
FI100799B (fi) Menetelmä terapeuttisesti aktiivisten tetraliinijohdannaisten valmista miseksi
NO174774C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive benzodiazepiner
HU908400D0 (en) Process for the production of imidazo(4,5-c)pyridine derivatives and medical preparations containing these compounds as active agents
NO172495C (no) Fremgangsmaate for fremstilling av terapeutisk aktive, ikke-mettede aminosyreforbindelser
FI900145L (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI871535A7 (fi) Menetelmä terapeuttisesti aktiivisten tiasykloalkeno/3,2-b/pyridiinien valmistamiseksi
FI890478A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4-okso-4H-pyrido/1,2-a/pyrimidiini-3-karboksamidijohdannaisten valmistamiseksi